Market Overview

UPDATE: Piper Jaffray Initiates ZIOPHARM Oncology at Neutral on 2013 Cancer Development Outlook

Share:
Related ZIOP
28 Stocks Moving In Monday's Pre-Market Session
9 Notable Biotechs Presenting At This Year's ASH Meeting

Piper Jaffray initiated coverage on ZIOPHARM Oncology (NASDAQ: ZIOP) with a Neutral rating and a $5.00 price target.

Piper Jaffray said, "The company's management deploys its considerable oncology network to focus on developing improved chemotherapeutics, and we believe its lead candidate palifosfamide (pali', DNA-alkylator), will succeed in at least one indication based on clinical rationale and early data. Pali' is currently in two Phase III studies, for 1st-line soft tissue sarcoma (STS) and for 1st-line small-cell lung cancer (SCLC). That said, we are not sufficiently convinced by the stated PFS-driven regulatory strategy to make a call on the near term pivotal PFS data in STS."

ZIOPHARM Oncology closed at $4.18 on Thursday.

Latest Ratings for ZIOP

DateFirmActionFromTo
Jun 2017H.C. WainwrightInitiates Coverage OnBuy
Aug 2016Wells FargoUpgradesUnderperformMarket Perform
Jun 2016Raymond JamesInitiates Coverage onMarket Perform

View More Analyst Ratings for ZIOP
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ZIOP)

View Comments and Join the Discussion!